Remdesivir gets FDA approval for Gilead

Remdesivir gets FDA approval for Gilead

The United States Food and Drug Administration has approved remdesivir for the treatment of coronavirus infection, the drug’s maker, Gilead Sciences, said.

Remdesivir, which was developed by Gilead as a treatment for Ebola, works to stop the replication of SARS-CoV-2, the coronavirus that causes COVID-19.

“In the United States, Veklury is indicated for adults and pediatric patients (12 years of age and older and weighing at least 40 kg) for the treatment of COVID-19 requiring hospitalization,” the company said in a statement. “Veklury should only be administered in a hospital or in a healthcare setting capable of providing acute care comparable to inpatient hospital care.”

The drug, sold under the brand name Veklury, has been used under emergency use authorization since May.

The drug was also recently touted by President Donald Trump.

Share on facebook
Facebook
Share on twitter
Twitter
Share on linkedin
LinkedIn

multimedia